Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon?

Abstract

Chronic hepatitis B (CHB) in serum HBeAg negative patients is a difficult to cure, progressive disease leading to end-stage liver disease and hepatocellular carcinoma. Currently, there are two different treatment strategies for such patients: a finite course of Pegylated interferon (PEG-IFN) or long-term administration of the more potent and less resistance… (More)
DOI: 10.1111/liv.12064

Topics

Cite this paper

@article{Lampertico2013WhyDI, title={Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon?}, author={Pietro Lampertico and Mauro Vigan{\'o} and Massimo G. Colombo}, journal={Liver international : official journal of the International Association for the Study of the Liver}, year={2013}, volume={33 Suppl 1}, pages={157-63} }